How to get funding without giving up equity

Why dilution costs more than you think

Before getting into the alternatives, it's worth understanding what you're actually giving up when you sell equity.

Say you raise €1M at a €4M pre-money valuation. You've just given up 20% of your company. If your company exits for €20M, that single round cost you €4M in proceeds, not €1M.

Dilution compounds. Early shares are the most expensive shares you'll ever sell. A 10% stake given away in a seed round could be worth 5x that in a Series B context, and 20x more at exit.

That doesn't mean going with equity is wrong. There are plenty of use cases where equity is the right and only choice to make. Sometimes the investor brings more than money. However, it does mean the question is worth asking: can I get to the same milestone without giving up ownership?

In some cases, the answer is yes. Equity is one of many options, and not the default.

6 ways to get funding without giving up equity

1. Bootstrapping

Best for: Early-stage founders, pre-revenue, or companies with low initial capital needs.

Bootstrapping means funding your company using your own resources: personal savings, operating revenue, or a combination of both. It's the oldest form of non-dilutive funding, and the most unambiguous. You own 100% because nobody else contributed.

The constraint is obvious: it limits how fast you can grow. Bootstrapping works best when your cost structure is lean, your sales cycle is short, and you can reinvest revenue quickly. SaaS companies often bootstrap to their first €500K-€1M ARR before looking at external capital.

The real advantage is the discipline it forces. Bootstrapped teams tend to be leaner, more capital-efficient, and better at prioritizing revenue. These are assets in any funding conversation down the line.

The honest trade-off: You're slower to scale. If you're in a winner-take-all market with a well-funded competitor, bootstrapping might cost you more than dilution would.

2. Debt funding (business loans and credit lines)

Best for: Companies with at least 6 months of operating history, predictable cash flow, and a clear use case for capital.

Debt financing is the most straightforward non-dilutive option: you borrow money and pay it back, with interest. You keep your shares. The lender keeps no stake in your upside.

Traditional business loans from banks are one form of this, but they're slow, require collateral, and are often inaccessible to early-stage tech companies and startups. The more relevant option for startups is flexible debt from lenders like re:cap, which provide credit lines based on your financial performance and revenue forecast rather than physical assets.

With re:cap, for example, you can access up to €5M in non-dilutive debt with customizable repayment periods (12 to 60 months), grace periods, and no equity warrants. The process is faster than a bank loan and doesn't require a personal guarantee.

Use cases

• Extend runway between equity rounds
• Fund a marketing push or an event with predictable ROI
• Create a cash buffer before a seasonal dip
• Grow into profitability

The honest trade-off: You're taking on repayment obligations. If revenue drops significantly, those obligations don't go away. Debt only makes sense when you have reasonable confidence in your ability to service it.

3. Revenue-Based Financing (RBF)

Best for: SaaS and subscription companies with recurring revenue, typically €250K+ ARR.

Revenue-based financing gives you capital upfront in exchange for a percentage of future revenue, not equity. You repay a fixed multiple (usually 1.3x-2x) of what you borrowed, paid as a share of monthly revenue (often 5-15%) until the cap is reached.

If revenue grows, you repay faster. If revenue contracts, payments contract too. There's no fixed monthly installment, no board seat, no warrant.

Example RBF

‍A SaaS company with €600K ARR borrows €300K at a 1.5x cap and a 10% revenue share. Monthly repayment fluctuates with revenue – roughly €5,000-€8,000/month – until €450K is repaid. Compare that to giving up 10% of your company in a round: at a €10M valuation, that 10% is worth €1M. RBF cost you €150K.

The honest trade-off: RBF typically costs more than a traditional loan on a per-euro basis. The flexibility premium is real. It also requires a revenue track record. It doesn't work for pre-revenue companies.

4. Venture Debt

Best for: VC-backed startups that want to extend runway without dilution between equity rounds.

Venture debt is debt financing designed specifically for venture-backed companies. It typically provides 25-35% of your last equity round as a term loan, at interest rates of 8-20%, often with a small warrant component (1-5% dilution).

It's not fully non-dilutive. Warrants mean you're giving up a small slice, but compared to raising a full equity round, it's dramatically less dilutive.

The classic use case

‍You raised a Series A 8 months ago. You have 4 months of runway left but need 8 months to hit the metrics that justify a strong Series B. Venture debt buys you those 4 months for less than 2% dilution, instead of forcing you into a down round or a dilutive bridge.

Venture debt typically requires recent VC backing. Lenders underwrite based on your investors' credibility as much as your own financials. If you're bootstrapped or haven't raised institutional equity, this option probably isn't available to you.

The honest trade-off: Warrants aside, venture debt comes with covenants. These are contractual restrictions that protect the lender. Violating them can trigger early repayment. It's not "free money," and misuse (e.g., taking venture debt to fund speculative bets rather than extend runway) can make a bad situation worse.

5. Grants and public funding

Best for: Deep tech, research-intensive, or innovation-driven startups with a connection to a specific mission or industry.

Grants are genuinely non-dilutive: you don't repay them, and you don't give up shares. The catch is that they're competitive, slow, and often come with strings attached (specific use cases, reporting requirements, sometimes IP rights).

In Germany and Europe, options include Horizon Europe, EXIST, KfW programs, and various regional innovation grants. In the UK, Innovate UK runs competitive grant programs.

R&D tax credits (like the German Forschungslagenförderung or UK RDEC) are another form of non-dilutive public funding. They reduce tax liability rather than provide upfront capital, but the effect on cash flow is real.

The honest trade-off: Grant applications are time-intensive. Winning a grant often takes 6-18 months from application to funding. This makes grants a poor choice for urgent capital needs, but a valuable complement for companies with a research or innovation component that fits specific programs.

6. Friends, Family, and Crowdfunding

Best for: Very early-stage companies, pre-product, or those building community-driven products.

Friends and family loans are often the first external capital a founder raises. Structured as a loan rather than equity investment, they're fully non-dilutive. The main risk is personal: mixing money and relationships carries its own costs.

Rewards-based crowdfunding (Kickstarter, Indiegogo) lets you raise from a broad base of supporters who receive a product or perk rather than equity. This works particularly well for physical product companies or consumer brands with a built-in community. It's not typically a large capital source, but it validates demand and generates cash simultaneously.

The honest trade-off: Neither of these scales. They're bridges, not sustainable funding strategies. If your capital need is meaningful (€500K+), you'll need to layer in more structured instruments.

How to choose the right funding option

The right non-dilutive instrument depends on three things: where you are in your journey, how much you need, and what you're using it for.

‍

The most common mistake founders make is treating these options as mutually exclusive. They aren't. A SaaS company at €1M ARR might combine a re:cap credit line for growth capital, an R&D tax credit to offset development costs, and a grants application running in parallel for a future innovation project. Each instrument plays a different role in the capital stack.

When non-dilutive funding doesn't make sense

Non-dilutive funding isn't always the right answer. Here's when equity financing is the better choice:

• You're pre-revenue and need significant capital.
  
  • Debt requires repayment. If you have no revenue and no clear path to generating it within 12-18 months, taking on debt is risky. Equity investors bear the downside risk with you; lenders don't.
• You need more than capital.
  
  • Some investors bring introductions, talent networks, and market access that money can't buy. If a specific investor's involvement would materially change your trajectory, the dilution might be worth it.
• You're in a market where speed is everything.
  
  • If you're competing in a winner-take-all race and need to outspend competitors to win, the relatively limited scale of most non-dilutive instruments might not be enough.
• You're raising for a potential acqui-hire or acquirer relationship.
  
  • Strategic investors sometimes serve a function beyond capital.

The goal is to avoid giving it up before you have to, or to use non-dilutive capital to delay equity rounds until you can negotiate from a stronger position.

When to combine non-dilutive and equity funding

Non-dilutive and equity funding are complements. Many of the best-run startups use both deliberately.

The common pattern: use non-dilutive capital to hit a milestone, then raise equity at a higher valuation from a position of strength. The dilution you take in the equity round is smaller because your metrics are better. The debt that got you there costs you a fraction of what the equity would have.